article Open AccessTop 1% cited
A Consensus Molecular Classification of Muscle-invasive Bladder Cancer
European Urology · 2019 · Vol. 77(4) · pp. 420–433
Aurélie Kamoun✉(La Ligue Contre le Cancer)Aurélien de Reyniès(La Ligue Contre le Cancer)Yves Allory(Centre National de la Recherche Scientifique)Gottfrid Sjödahl(Lund University)A. Gordon Robertson(BC Cancer Agency)Roland Seiler(University Hospital of Bern)Katherine A. Hoadley(University of North Carolina at Chapel Hill)Clarice S. Groeneveld(Centre National de la Recherche Scientifique)Hikmat Al-Ahmadie(Memorial Sloan Kettering Cancer Center)Woonyoung Choi(Johns Hopkins University)Mauro A.A. Castro(Universidade Federal do Paraná)Jacqueline Fontugne(Centre National de la Recherche Scientifique)Pontus Eriksson(Lund University)Qianxing Mo(Moffitt Cancer Center)Jordan Kardos(University of North Carolina at Chapel Hill)Alexandre Zlotta(Mount Sinai Hospital)Arndt Hartmann(Friedrich-Alexander-Universität Erlangen-Nürnberg)Colin P. Dinney(The University of Texas MD Anderson Cancer Center)Joaquim Bellmunt(Harvard University)Thomas Powles(Queen Mary University of London)Núria Malats(BC Cancer Agency)Keith Syson Chan(Cedars-Sinai Medical Center)William Y. Kim(University of North Carolina at Chapel Hill)David J. McConkey(Johns Hopkins University)Peter C. Black(University of British Columbia)Lars Dyrskjøt(Aarhus University Hospital)Mattias Höglund(Lund University)Seth P. Lerner(Baylor College of Medicine)Francisco X. Real(Spanish National Cancer Research Centre)François Radvanyi(Centre National de la Recherche Scientifique)Mattias AineHikmat Al-Ahmadie(Memorial Sloan Kettering Cancer Center)Yves Allory(Centre National de la Recherche Scientifique)Joaquim Bellmunt(Harvard University)Isabelle Bernard-Pierrot(Laboratoire de Biologie et Modélisation de la Cellule)Peter C. Black(University of British Columbia)Mauro A.A. Castro(Universidade Federal do Paraná)Keith Syson Chan(Cedars-Sinai Medical Center)Woonyoung Choi(Johns Hopkins University)Bogdan CzerniakColin P. Dinney(The University of Texas MD Anderson Cancer Center)Lars Dyrskjøt(Aarhus University Hospital)Pontus Eriksson(Lund University)Jacqueline Fontugne(Centre National de la Recherche Scientifique)Ewan A. GibbClarice S. Groeneveld(Centre National de la Recherche Scientifique)Arndt Hartmann(Friedrich-Alexander-Universität Erlangen-Nürnberg)Katherine A. Hoadley(University of North Carolina at Chapel Hill)Mattias Höglund(Lund University)Aurélie Kamoun✉(La Ligue Contre le Cancer)Jordan Kardos(University of North Carolina at Chapel Hill)Jaegil Kim(University of North Carolina at Chapel Hill)William Y. Kim(University of North Carolina at Chapel Hill)David J. KwiatkowskiThierry Lebrét(Université de Versailles Saint-Quentin-en-Yvelines)Seth P. Lerner(Baylor College of Medicine)Fredrik LiedbergNúria Malats(BC Cancer Agency)David J. McConkey(Johns Hopkins University)Qianxing Mo(Moffitt Cancer Center)Thomas Powles(Queen Mary University of London)François Radvanyi(Centre National de la Recherche Scientifique)Francisco X. Real(Spanish National Cancer Research Centre)Aurélien de Reyniès(La Ligue Contre le Cancer)A. Gordon Robertson(BC Cancer Agency)Arlene O. Siefker‐RadtkeNanor Sirab(Hôpital René Huguenin)Roland Seiler(University Hospital of Bern)Gottfrid Sjödahl(Lund University)Ann Taber(Friedrich-Alexander-Universität Erlangen-Nürnberg)John N. WeinsteinAlexandre Zlotta(Mount Sinai Hospital)
Abstract
Bladder cancers are heterogeneous at the molecular level, and scientists have proposed several classifications into sets of molecular classes. While these classifications may be useful to stratify patients for prognosis or response to treatment, a consensus classification would facilitate the clinical use of molecular classes. Conducted by multidisciplinary expert teams in the field, this study proposes such a consensus and provides a tool for applying the consensus classification in the clinical setting.
Bladder and Urothelial Cancer TreatmentsFerroptosis and cancer prognosisCancer, Lipids, and MetabolismMedicineBladder cancerClinical trialDiseaseBioinformaticsComputational biologyOncologyInternal medicineCancerBiology
MeSH terms
AgedAged, 80 and overUrinary Bladder NeoplasmsFemaleHumansMaleMiddle AgedNeoplasm InvasivenessRetrospective StudiesConsensus
Funding
- Cancerfonden
- National Human Genome Research Institute
- National Cancer Institute
Citations
1,318
FWCI
136.73
field-weighted impact
References
43
Percentile
100%
vs. same field & year
Citations per year
Cited by
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
European Urology · 2020 · 2,116 citations
References
The consensus molecular subtypes of colorectal cancer
Nature Medicine · 2015 · 5,121 citations
Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy
Cancer Cell · 2014 · 1,717 citations
A Molecular Taxonomy for Urothelial Carcinoma
Clinical Cancer Research · 2012 · 986 citations
Inferring tumour purity and stromal and immune cell admixture from expression data
Nature Communications · 2013 · 10,540 citations
Role of cell cycle in mediating sensitivity to radiotherapy
International Journal of Radiation Oncology*Biology*Physics · 2004 · 1,070 citations
Absolute quantification of somatic DNA alterations in human cancer
Nature Biotechnology · 2012 · 2,193 citations
Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression
Genome biology · 2016 · 3,923 citations
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
European Urology · 2017 · 780 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.
